Published in Leukemia on August 17, 2006
Medicine must change to serve an ageing society. Eradicate age discrimination and increase resources. BMJ (1999) 3.43
The role of letters in reviewing research. BMJ (1994) 3.26
Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood (2001) 2.61
Pregnancy's toll in the developing world. BMJ (1994) 2.50
Amplification of mitochondrial DNA in acute myeloid leukaemia. Br J Haematol (1996) 2.17
Investigation and management of pulmonary infiltrates following bone marrow transplantation: an eight year review. Thorax (1993) 2.08
Reviewers chosen by authors. BMJ (1995) 2.05
Dielectrophoretic separation and enrichment of CD34+ cell subpopulation from bone marrow and peripheral blood stem cells. Med Biol Eng Comput (1995) 1.68
Unravelling an HLA-DR association in childhood acute lymphoblastic leukemia. Blood (1999) 1.68
The dielectrophoresis enrichment of CD34+ cells from peripheral blood stem cell harvests. Bone Marrow Transplant (1996) 1.65
Consensus Conference on Intensive Chemotherapy Plus Hematopoietic Stem-Cell Transplantation in Malignancies: Lyon, France, June 4-6, 1993. J Clin Oncol (1994) 1.63
Honey stimulates inflammatory cytokine production from monocytes. Cytokine (2003) 1.63
Comparison of 'sequential' versus 'standard' chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial. Br J Haematol (2001) 1.58
Information management and patient privacy in the NHS. BMJ (1993) 1.51
TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis. Leukemia (2008) 1.50
CD200 as a prognostic factor in acute myeloid leukaemia. Leukemia (2007) 1.49
Revised guidelines for HIV infected health workers. BMJ (1993) 1.43
Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis. Eur J Heart Fail (2002) 1.40
Transplantation in first remission of acute myeloid leukemia. N Engl J Med (1998) 1.39
Third party mediated graft rejection despite irradiation of blood products. Br J Haematol (1992) 1.39
Transcriptional dysregulation mediated by RUNX1-RUNX1T1 in normal human progenitor cells and in acute myeloid leukaemia. Leukemia (2007) 1.29
Alleles at D6S265 and D6S105 define a haemochromatosis-specific genotype. Br J Haematol (1994) 1.23
An ethics committee for the BMJ. BMJ (2000) 1.19
A 5.8-kDa component of manuka honey stimulates immune cells via TLR4. J Leukoc Biol (2007) 1.17
Mutant N-RAS induces erythroid lineage dysplasia in human CD34+ cells. J Exp Med (1997) 1.11
Incidence of AML1/ETO fusion transcripts in patients entered into the MRC AML trials. MRC Adult Leukaemia Working Party. Br J Haematol (1997) 1.10
Information in practice. BMJ (1996) 1.08
Molecular mimicry of an HLA-DR53 epitope by viruses. Immunol Today (1994) 1.08
CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia. Leukemia (2011) 1.07
The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia. Leukemia (2013) 1.07
Neisseria catarrhalis septicaemia in acute lymphoblastic leukaemia. Scott Med J (1975) 1.06
Elder abuse. BMJ (1999) 1.04
Adverse impact of bone marrow transplantation on quality of life in acute myeloid leukaemia patients; analysis of the UK Medical Research Council AML 10 Trial. Eur J Cancer (2004) 1.04
c-myc locus amplification and the acquisition of trisomy 8 in the evolution of chronic myeloid leukaemia. Leuk Res (1998) 1.03
The effect of lithium therapy on parameters thought to be involved in the development of autoimmune thyroid disease. Clin Endocrinol (Oxf) (1991) 1.02
Community care in Northern Ireland: a promising start. BMJ (1994) 0.98
Expression of AML1-ETO in human myelomonocytic cells selectively inhibits granulocytic differentiation and promotes their self-renewal. Leukemia (2004) 0.98
New ambulance targets could save 3000 lives a year. BMJ (1995) 0.96
Plasma-exchange combined with immunosuppressive therapy in myasthenia gravis. Lancet (1979) 0.95
Invasive aspergillosis localised to the colon presenting as toxic megacolon. Eur J Haematol (2007) 0.95
Iron overload and liver dysfunction after allogeneic or autologous bone marrow transplantation. Bone Marrow Transplant (1996) 0.95
The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML cells and is highly synergistic with cytarabine. Leukemia (2011) 0.94
Frequency of CBF beta/MYH11 fusion transcripts in patients entered into the U.K. MRC AML trials. The MRC Adult Leukaemia Working Party. Br J Haematol (1997) 0.94
Congenital abdominal wall defects in the United Kingdom. Analysis should be restricted to regional data. BMJ (1999) 0.93
Increased CD200 expression in acute myeloid leukemia is linked with an increased frequency of FoxP3+ regulatory T cells. Leukemia (2012) 0.91
Elevated Bcr-Abl expression levels are sufficient for a haematopoietic cell line to acquire a drug-resistant phenotype. Leukemia (2001) 0.91
A new approach to the classification of human leukaemias: measurement of the relative abundance of a specific RNA sequence by means of molecular hybridisation. Lancet (1983) 0.89
Abnormalities of adherent layers grown from bone marrow of patients with myelodysplasia. Br J Haematol (2000) 0.89
Frequency of clonal remission in acute myeloid leukaemia. Lancet (1993) 0.88
DNA methylation: biology and significance. Blood Rev (1996) 0.88
Outcome following prenatal diagnosis of complete atrioventricular septal defect. Prenat Diagn (2008) 0.87
Subclinical pulmonary function defects following autologous and allogeneic bone marrow transplantation: relationship to total body irradiation and graft-versus-host disease. Int J Radiat Oncol Biol Phys (1991) 0.87
Plasma exchange in Guillain-Barré syndrome. Br Med J (Clin Res Ed) (1981) 0.87
Two new polymorphisms but no mutations of the KIT gene in patients with myelodysplasia at positions corresponding to human FMS and murine W locus mutational hot spots. Leukemia (1993) 0.87
Seronegative blood products prevent primary cytomegalovirus infection after bone marrow transplantation. J Clin Pathol (1988) 0.86
Expression of CD200 on AML blasts directly suppresses memory T-cell function. Leukemia (2012) 0.86
γ-Catenin is overexpressed in acute myeloid leukemia and promotes the stabilization and nuclear localization of β-catenin. Leukemia (2012) 0.85
Mutant RAS inhibits neutrophil but not macrophage differentiation and allows continued growth of neutrophil precursors. Exp Hematol (1999) 0.85
Randomised vehicle-controlled dose-finding study of glycosylated recombinant human granulocyte colony-stimulating factor after bone marrow transplantation. Bone Marrow Transplant (1993) 0.85
No evidence for microsatellite instability or consistent loss of heterozygosity at selected loci in chronic myeloid leukaemia blast crisis. Leukemia (1994) 0.84
Genome-wide profiling of methylation identifies novel targets with aberrant hypermethylation and reduced expression in low-risk myelodysplastic syndromes. Leukemia (2012) 0.84
Nucleic acid composition of bone marrow mononuclear cells in cobalamin deficiency. Blood (1996) 0.84
Increased heterozygosity for MHC class II lineages in newborn males. Genes Immun (2002) 0.84
Who may give blood? Br Med J (Clin Res Ed) (1987) 0.84
Nature of HLA-associated predisposition to childhood acute lymphoblastic leukemia. Leukemia (1995) 0.84
Inhibition of mitochondrial function in HL60 cells is associated with an increased apoptosis and expression of CD14. Biochem Biophys Res Commun (1999) 0.84
An epidemiological study of holoprosencephaly from a regional congenital anomaly register: 1995-2004. Prenat Diagn (2007) 0.84
Merck offers money back guarantee on finasteride. BMJ (1994) 0.84
OGG1 is a novel prognostic indicator in acute myeloid leukaemia. Oncogene (2009) 0.83